Hospital pharmacies held the dominant position in the non-alcoholic steatohepatitis treatment market in 2025, accounting for a 61.18% share. This channel remains dominant because treatment initiation, disease assessment, and therapy monitoring for non-alcoholic steatohepatitis are closely tied to hospital-based care pathways, where patients are more likely to undergo specialist evaluation and receive coordinated management. The concentration of prescribing physicians, diagnostic workflows, and pharmacy dispensing within hospital settings supports consistent volume through this channel and helps sustain its leadership in the market.

Retail and specialty pharmacies are emerging as the fastest-growing channel in the non-alcoholic steatohepatitis treatment market as patient management gradually extends beyond acute care environments into more distributed treatment access models. Their growth is being backed by the practical need for convenient refill access, continuity for longer-duration therapy, and closer alignment with outpatient treatment journeys. Compared with hospital pharmacies, retail and specialty pharmacies are gaining momentum because they are better positioned to support ongoing access once patients move from diagnosis and initiation toward sustained disease management.

Disease Stage Segment Analysis: NASH Stage F1 (Largest Segment) vs NASH Stage F0 (Fastest-Growing Segment)

In 2025, NASH Stage F1 represented the largest disease stage segment in the non-alcoholic steatohepatitis treatment market, with a 36.84% share. Its leadership reflects the point at which disease progression becomes more clinically actionable, creating clearer treatment engagement than at earlier stages while still representing a sizeable patient population. In practical terms, this stage sits at an important intersection of diagnosis and intervention, where physicians are more likely to initiate management strategies aimed at slowing further liver damage, helping NASH Stage F1 maintain its leading share in the market.

NASH Stage F0 is the fastest-growing segment in the non-alcoholic steatohepatitis treatment market as clinical attention increasingly shifts toward earlier identification and intervention before fibrosis advances. Growth at this stage is being driven by the rising practical value of acting sooner in the disease course, particularly as care models place greater emphasis on monitoring at-risk patients and managing progression earlier than in the past. Relative to later stages, NASH Stage F0 is gaining traction because it aligns with a more proactive treatment approach centered on early-stage patient capture and timely therapeutic decision-making.